<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1335">
  <stage>Registered</stage>
  <submitdate>6/03/2001</submitdate>
  <approvaldate>6/03/2001</approvaldate>
  <actrnumber>ACTRN12606000252516</actrnumber>
  <trial_identification>
    <studytitle>Australasian Collaborative Trial of Magnesium Sulphate for the Prevention of Mortality and Cerebral Palsy in Infants Born Very Preterm.</studytitle>
    <scientifictitle>Australasian Collaborative Trial of Magnesium Sulphate for the Prevention of Mortality and Cerebral Palsy in Infants Born Very Preterm.</scientifictitle>
    <utrn />
    <trialacronym>ACTOMgSO4</trialacronym>
    <secondaryid>Perinatal Trials Registry: PTR354</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infants born very preterm (&lt;30 weeks)</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment group: Magnesium sulphate (2mmol/mL).
Dosing regimen for both groups: Loading infusion: 8 mLs over 20mins via infusion pump. Maintenance: 2mLs/hr until delivery or 24 hrs whichever is longer</interventions>
    <comparator>Placebo group: Normal saline
Dosing regimen for both groups: Loading infusion: 8 mLs over 20mins via infusion pump. Maintenance: 2mLs/hr until delivery or 24 hrs whichever is longer</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cerebral palsy</outcome>
      <timepoint>2 years corrected age</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Neonatal infant survival</outcome>
      <timepoint>Up to 2 years of age</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Death or Cerebral Palsy</outcome>
      <timepoint>Early School Age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebroventricular haemmorhage</outcome>
      <timepoint>Up to time of primary hospital discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Periventricular leukomalacia</outcome>
      <timepoint>Up to time of primary hospital discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maternal morbidity</outcome>
      <timepoint>Up to 6 weeks postnatal.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnant women &lt;30 weeks where delivery is planned or definately expected within 24 hours.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindications to magnesium sulphate; in second stage of labour; previous magnesium sulphate therapy in the pregnancy and magnesium sulphate therapy considered essential</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered Containers: packs identical in appearance, labelled with unique study number by independent third party</concealment>
    <sequence>Stratified Allocation: stratified by centre and plurality (singleton. twin, higher-order multiple). Computer generated sequence with variable block sizes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>29/02/1996</anticipatedstartdate>
    <actualstartdate>29/02/1996</actualstartdate>
    <anticipatedenddate />
    <actualenddate>15/09/2000</actualenddate>
    <samplesize>1178</samplesize>
    <actualsamplesize>1178</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,NT,QLD,SA,TAS,WA</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Caroline Crowther</primarysponsorname>
    <primarysponsoraddress>Women's &amp; Children's Hospital
72 King William Rd
North Adelaide  SA  5006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council 5 yr Epidemiology Grant</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Channel 7 Research Foundation of South Australia Inc</fundingname>
      <fundingaddress>171 Days Rd
Regency Park SA 5010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Queen Victoria Hospital Research Foundation</fundingname>
      <fundingaddress>Queen Victoria Hospital
Fullarton Rd  
Rose Park  SA  5067</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Janet Hiller</sponsorname>
      <sponsoraddress>University of Adelaide
North Tce, Adelaide SA  5005</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Lex Doyle</sponsorname>
      <sponsoraddress>The Royal Women's Hospital
cnr Grattan St &amp; Flemington Rd
Parkville  Vic  3052</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Ross Haslam</sponsorname>
      <sponsoraddress>Women's &amp; Children's Hospital
72 King William Rd
North Adelaide  SA  5006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Infants born preterm have an increased risk of mortality and cerebral
palsy. Evidence from recent case controlled studies support animal
research that suggests maternal administration of magnesium sulphate may
reduce the risk of cerebral palsy and mortality in infants born very
preterm. It is important that these findings are tested in large
randomised controlled trials as soon as possible to assess whether
prophylactic treatment should be recommedned for clinical practice in
the case of women who are at risk of preterm delivery. Trial participants, trial research staff and all involved in clinical
care of participants were blinded.  
Trial treatment packs of identical appearance, labelled only with unique
study number.</summary>
    <trialwebsite />
    <publication>Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
Crowther CA, Hiller JE, Doyle LW, Haslam RR; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group..
JAMA. 2003 Nov 26;290(20):2669-76

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo.
Doyle LW, Anderson PJ, Haslam R, Lee KJ, Crowther C; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group..
JAMA. 2014 Sep 17;312(11):1105-13. doi: 10.1001/jama.2014.11189.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Women's &amp; Children's Hospital, Maternal Perinatal Clinical Trials Unit Adelaide University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/12/1995</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/1335-Crowther et al.  JAMA 2003 ACTOMgSO4 Trial.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/1335-Doyle et al JAMA 2014.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Caroline Crowther</name>
      <address>University Obstetrics &amp; Gynaecology
Women's &amp; Children's Hospital
Queen Victoria Building
Level 1
72 King William Road
North Adelaide SA 5006</address>
      <phone>+61 8 8161 7619</phone>
      <fax>+61 8 81617652</fax>
      <email>caroline.crowther@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Caroline Crowther</name>
      <address>University Obstetrics &amp; Gynaecology
Women's &amp; Children's Hospital
Queen Victoria Building
Level 1
72 King William Road
North Adelaide SA 5006</address>
      <phone>+61 8 8161 7619</phone>
      <fax>+61 8 81617652</fax>
      <email>caroline.crowther@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Caroline Crowther</name>
      <address>Women's &amp; Children's Hospital
72 King William Rd
North Ade.laide  SA  5006</address>
      <phone>+61 8 8161 7619</phone>
      <fax />
      <email>caroline.crowther@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>